Your browser doesn't support javascript.
Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach.
Charitou, Theodosia; Kontou, Panagiota I; Tamposis, Ioannis A; Pavlopoulos, Georgios A; Braliou, Georgia G; Bagos, Pantelis G.
  • Charitou T; Computer Science and Biomedical Informatics, University of Thessaly, Lamia, 35131, Greece.
  • Kontou PI; Mathematics, University of Thessaly, Lamia, 35131, Greece.
  • Tamposis IA; Computer Science and Biomedical Informatics, University of Thessaly, Lamia, 35131, Greece.
  • Pavlopoulos GA; Institute for Fundamental Biomedical Research, BSRC "Alexander Fleming", Vari, Greece.
  • Braliou GG; Center of New Biotechnologies & Precision Medicine, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
  • Bagos PG; Computer Science and Biomedical Informatics, University of Thessaly, Lamia, 35131, Greece.
Pharmacogenomics J ; 22(5-6): 294-302, 2022 12.
Article in English | MEDLINE | ID: covidwho-2050328
ABSTRACT
Available drugs have been used as an urgent attempt through clinical trials to minimize severe cases of hospitalizations with Coronavirus disease (COVID-19), however, there are limited data on common pharmacogenomics affecting concomitant medications response in patients with comorbidities. To identify the genomic determinants that influence COVID-19 susceptibility, we use a computational, statistical, and network biology approach to analyze relationships of ineffective concomitant medication with an adverse effect on patients. We statistically construct a pharmacogenetic/biomarker network with significant drug-gene interactions originating from gene-disease associations. Investigation of the predicted pharmacogenes encompassing the gene-disease-gene pharmacogenomics (PGx) network suggests that these genes could play a significant role in COVID-19 clinical manifestation due to their association with autoimmune, metabolic, neurological, cardiovascular, and degenerative disorders, some of which have been reported to be crucial comorbidities in a COVID-19 patient.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Pharmacogenomics J Journal subject: Molecular Biology / Pharmacology Year: 2022 Document Type: Article Affiliation country: S41397-022-00289-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Prognostic study / Reviews Limits: Humans Language: English Journal: Pharmacogenomics J Journal subject: Molecular Biology / Pharmacology Year: 2022 Document Type: Article Affiliation country: S41397-022-00289-1